89 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
A treatment and prophylaxis, and the potential efficacy and clinical benefits of, and market for, such product candidates. The words “believe,” “may
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
and norovirus and the Phase 1 study for such product candidate, the potential efficacy and clinical benefits of, and market for, such product candidates
8-K
EX-99.1
inp xnwh2y4r
6 Dec 23
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
8:00am
8-K
EX-99.2
kzxnix2id svnkt
29 Nov 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
1ow9wabo oj3cwx
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
EX-1.1
5h6rhs1nl4ghv
5 May 21
Entry into a Material Definitive Agreement
5:02pm
8-K
EX-99.2
jhiijf
2 Oct 20
Other Events
8:00am
8-K
EX-1.1
rjhz84
27 Aug 20
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-1.1
61s4b9e
2 Jul 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-10.1
rj7a2ytm
13 Mar 20
Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market
4:44pm
8-K
EX-10.2
913c4peqtfalz n5
4 Mar 20
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market
5:09pm
8-K
EX-10.1
990lb7r
4 Mar 20
Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market
5:09pm
8-K
EX-1.1
9l8d50udd8bbj 8akp5
31 Jan 20
Entry into a Material Definitive Agreement
8:01am
8-K
EX-10.1
9wuem2ywi36vh4bi 2b
31 Jan 20
Entry into a Material Definitive Agreement
8:01am